{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:44:17Z","timestamp":1760143457916,"version":"build-2065373602"},"reference-count":61,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics and Practice"],"abstract":"<jats:p>Background and objectives: Atrial fibrillation (AF) is a common arrhythmia associated with various risk factors and significant morbidity and mortality. Materials and methods: This article presents findings from a study involving 345 patients with permanent AF. This study examined demographics, risk factors, associated pathologies, complications, and anticoagulant therapy over the course of a year. Results: The results showed a slight predominance of AF in males (55%), with the highest incidence in individuals aged 75 and older (49%). Common risk factors included arterial hypertension (54%), dyslipidemia, diabetes mellitus type 2 (19.13%), and obesity (15.65%). Comorbidities such as congestive heart failure (35.6%), mitral valve regurgitation (60%), and dilated cardiomyopathy (32%) were prevalent among the patients. Major complications included congestive heart failure (32%), stroke (17%), and myocardial infarction (5%). Thromboembolic and bleeding risk assessment using CHA2DS2-VASc and HAS-BLED scores demonstrated a high thromboembolic risk in all patients. The majority of patients were receiving novel oral anticoagulants (NOACs) before admission (73%), while NOACs were also the most prescribed antithrombotic therapy at discharge (61%). Conclusions: This study highlights the importance of risk factor management and appropriate anticoagulant therapy in patients with AF, to reduce complications and improve outcomes. The results support the importance of tailored therapeutic schemes, for optimal care of patients with AF.<\/jats:p>","DOI":"10.3390\/clinpract14010027","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T08:16:52Z","timestamp":1707725812000},"page":"344-360","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Optimizing Atrial Fibrillation Care: Comparative Assessment of Anticoagulant Therapies and Risk Factors"],"prefix":"10.3390","volume":"14","author":[{"given":"Marius","family":"Rus","sequence":"first","affiliation":[{"name":"Department of Medical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana Ioana","family":"Ardelean","sequence":"additional","affiliation":[{"name":"Department of Preclinical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simina","family":"Crisan","sequence":"additional","affiliation":[{"name":"Cardiology Department, \u201cVictor Babes\u201d University of Medicine and Pharmacy, 2 Eftimie Murgu Sq., 300041 Timisoara, Romania"},{"name":"Institute of Cardiovascular Diseases Timisoara, 13A Gheorghe Adam Street, 300310 Timisoara, Romania"},{"name":"Research Center of the Institute of Cardiovascular Diseases Timisoara, 13A Gheorghe Adam Street, 300310 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Marian","sequence":"additional","affiliation":[{"name":"Department of Medical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oana Lilliana","family":"Pobirci","sequence":"additional","affiliation":[{"name":"Department of Psycho Neuroscience and Recovery, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Huplea","sequence":"additional","affiliation":[{"name":"Department of Psycho Neuroscience and Recovery, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Judea Pusta","sequence":"additional","affiliation":[{"name":"Department of Morphological Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gheorghe Adrian","family":"Osiceanu","sequence":"additional","affiliation":[{"name":"Department of Morphological Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6749-0636","authenticated-orcid":false,"given":"Claudia Elena","family":"Stanis","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5670-3456","authenticated-orcid":false,"given":"Felicia Liana","family":"Andronie-Cioara","sequence":"additional","affiliation":[{"name":"Department of Psycho Neuroscience and Recovery, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Sagris, M., Vardas, E.P., Theofilis, P., Antonopoulos, A.S., Oikonomou, E., and Tousoulis, D. (2021). Atrial fibrillation: Pathogenesis, predisposing factors, and Genetics. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23010006"},{"key":"ref_2","unstructured":"Lascalzo, J., Fauci, A.S., Kasper, D.L., Longo, D.L., Braunwald, E., Hauser, S.L., and Jameson, J.L. (2010). Harrison\u2019s Cardiovascular Medicine, McGraw-Hill Medical."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Ramrakha, P., and Hill, J. (2012). Oxford Handbook of Cardiology, Oxford University Press Inc.. [2nd ed.].","DOI":"10.1093\/med\/9780199643219.001.0001"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (eacts)","volume":"42","author":"Hindricks","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_5","unstructured":"Griffin, B.P., and Zardkoohi, O. (2013). Manual of Cardiovascular Medicine., Lippincott Williams & Wilkins."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1161\/CIRCULATIONAHA.120.049768","article-title":"Stroke prevention in atrial fibrillation","volume":"142","author":"Katsanos","year":"2020","journal-title":"Circulation"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/jcpt.12122","article-title":"Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: Evidence and unanswered questions","volume":"39","author":"Cheng","year":"2014","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrcardio.2016.45","article-title":"Atrial fibrillation in women: Epidemiology, pathophysiology, presentation, and prognosis","volume":"13","author":"Ko","year":"2016","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e006350","DOI":"10.1161\/CIRCEP.118.006350","article-title":"Lifetime risk of atrial fibrillation by race and socioeconomic status: ARIC Study (Atherosclerosis Risk in Communities)","volume":"11","author":"Mou","year":"2018","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0140-6736(14)61774-8","article-title":"50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: A cohort study","volume":"386","author":"Schnabel","year":"2015","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/clc.4950250203","article-title":"Gender differences in arrhythmias","volume":"25","author":"Wolbrette","year":"2002","journal-title":"Clin. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2174\/1573403X15666181205110624","article-title":"Gender differences in atrial fibrillation: A review of Epidemiology, management, and outcomes","volume":"15","author":"Westerman","year":"2019","journal-title":"Curr. Cardiol. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.117.309732","article-title":"Atrial fibrillation","volume":"120","author":"Staerk","year":"2017","journal-title":"Circ. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1161\/CIRCULATIONAHA.114.008201","article-title":"Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through 2010","volume":"129","author":"Patel","year":"2014","journal-title":"Circulation"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1524-4733.2006.00124.x","article-title":"Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States","volume":"9","author":"Coyne","year":"2006","journal-title":"Value Health"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ahj.2016.11.008","article-title":"Multimorbidity and the risk of hospitalization and death in atrial fibrillation: A population-based study","volume":"185","author":"Chamberlain","year":"2017","journal-title":"Am. Heart J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/hrs guideline for the diagnosis and management of Atrial Fibrillation: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/joa3.12652","article-title":"2021 focused update of the 2017 consensus guidelines of the Asia Pacific Heart rhythm society (APHRS) on stroke prevention in atrial fibrillation","volume":"37","author":"Chao","year":"2021","journal-title":"J. Arrhythmia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1055\/s-0039-1693516","article-title":"Improved population-based clinical outcomes of patients with atrial fibrillation by compliance with the simple ABC (atrial fibrillation better care) pathway for Integrated Care Management: A nationwide cohort study","volume":"119","author":"Yoon","year":"2019","journal-title":"Thromb. Haemost."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"101757","DOI":"10.1016\/j.eclinm.2022.101757","article-title":"Adherence to the atrial fibrillation better care (ABC) pathway and the risk of major outcomes in patients with atrial fibrillation: A post-hoc analysis from the prospective Gloria-AF Registry","volume":"55","author":"Romiti","year":"2023","journal-title":"eClinicalMedicine"},{"key":"ref_21","first-page":"1730","article-title":"Evaluation of the atrial fibrillation better care pathway in the engage AF-TIMI 48 trial","volume":"24","author":"Patel","year":"2022","journal-title":"EP Eur."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jacasi.2023.04.008","article-title":"Integrated care for atrial fibrillation using the ABC pathway in the prospective APHRS-AF Registry","volume":"3","author":"Bucci","year":"2023","journal-title":"JACC Asia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1001\/jama.1994.03510350050036","article-title":"Independent risk factors for atrial fibrillation in a population-based cohort: The Framingham Heart Study","volume":"271","author":"Benjamin","year":"1994","journal-title":"JAMA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1161\/CIRCULATIONAHA.110.009035","article-title":"Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: The Atherosclerosis Risk in Communities (ARIC) study","volume":"123","author":"Huxley","year":"2011","journal-title":"Circulation"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e002197","DOI":"10.1161\/JAHA.115.002197","article-title":"Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: Data from ROCKET AF","volume":"5","author":"Pokorney","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e002015","DOI":"10.1161\/JAHA.115.002015","article-title":"Apixaban for Reduction in Sroke and Other Thromboembolic Events in Atrial Fibrillation Steering Committee and Investigators. Blood pressure control and risk of stroke or systemic embolism in patients with atrial fibrillation: Results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial","volume":"4","author":"Rao","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jcmg.2017.09.013","article-title":"Mitral valve adaptation to isolated annular dilation","volume":"12","author":"Kim","year":"2019","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.jacc.2011.06.033","article-title":"Atrial functional mitral regurgitation","volume":"58","author":"Hoit","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1161\/CIRCHEARTFAILURE.111.965681","article-title":"Presence of atrial fibrillation is independently associated with adverse outcomes in patients hospitalized with heart failure: An analysis of Get with The Guidelines\u2013Heart Failure","volume":"5","author":"Mountantonakis","year":"2012","journal-title":"Circ. Heart Fail."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/j.jacc.2011.07.036","article-title":"Cardiovascular outcomes in the AFFIRM trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management): An assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses","volume":"58","author":"Saksena","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1161\/01.CIR.0000072767.89944.6E","article-title":"Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham Heart Study","volume":"107","author":"Wang","year":"2003","journal-title":"Circulation"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.jchf.2019.03.005","article-title":"Heart failure and atrial fibrillation, like fire and fury","volume":"7","author":"Carlisle","year":"2019","journal-title":"JACC Heart Fail."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.amjcard.2021.08.042","article-title":"Prevention and treatment of atrial fibrillation via risk factor modification","volume":"160","author":"Sturgess","year":"2021","journal-title":"Am. J. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.ahj.2015.07.026","article-title":"Effect of an intensive lifestyle intervention on atrial fibrillation risk in individuals with type 2 diabetes: The look ahead randomized trial","volume":"170","author":"Alonso","year":"2015","journal-title":"Am. Heart J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.hrthm.2011.02.016","article-title":"Coronary artery disease affecting the atrial branches is an independent determinant of atrial fibrillation after myocardial infarction","volume":"8","author":"Alasady","year":"2011","journal-title":"Heart Rhythm."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1177\/2047487317715769","article-title":"Atrial fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: A systematic review and meta-analysis","volume":"24","author":"Ruddox","year":"2017","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"100360","DOI":"10.1016\/j.ijcha.2019.100360","article-title":"Outcome of atrial fibrillation ablation in pulmonary hypertension: Is pulmonary hypertension a modifiable risk factor?","volume":"23","author":"Linz","year":"2019","journal-title":"IJC Heart Vasc."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jjcc.2016.12.013","article-title":"Chronic obstructive pulmonary disease and atrial fibrillation: An unknown relationship","volume":"69","author":"Goudis","year":"2017","journal-title":"J. Cardiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ijcard.2018.03.099","article-title":"Type 1 and type 2 diabetes mellitus and incidence of seven cardiovascular diseases","volume":"262","author":"Larsson","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.amjcard.2011.03.004","article-title":"Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation","volume":"108","author":"Huxley","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1001\/jama.292.20.2471","article-title":"Obesity and the risk of new-onset atrial fibrillation","volume":"292","author":"Wang","year":"2004","journal-title":"JAMA"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/clc.22397","article-title":"Quality of anticoagulation with Vitamin K antagonists","volume":"38","author":"Anguita","year":"2015","journal-title":"Clin. Cardiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: The Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1161\/01.STR.27.10.1760","article-title":"Stroke severity in atrial fibrillation","volume":"27","author":"Lin","year":"1996","journal-title":"Fram. Study. Stroke"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5114\/aoms.2019.84212","article-title":"Atrial fibrillation risk factors in patients with ischemic stroke","volume":"17","author":"Nowacki","year":"2021","journal-title":"Arch. Med. Sci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e022478","DOI":"10.1136\/bmjopen-2018-022478","article-title":"Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: The prospective, multicentre observational prevention of thromboembolic events\u2014European registry in Atrial Fibrillation (prefer in AF)","volume":"9","author":"Rohla","year":"2019","journal-title":"BMJ Open"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1054\/jocn.2001.1018","article-title":"The morbidity related to atrial fibrillation at a Tertiary Centre in one year: 9.0% of all strokes are potentially preventable","volume":"9","author":"Evans","year":"2002","journal-title":"J. Clin. Neurosci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3988\/jcn.2022.0289","article-title":"Stroke-specific predictors of major bleeding in anticoagulated patients with stroke and atrial fibrillation: A nationwide Multicenter Registry-Based Study","volume":"19","author":"Chung","year":"2023","journal-title":"J. Clin. Neurol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"757087","DOI":"10.3389\/fcvm.2021.757087","article-title":"Diagnostic accuracy of the has-bled bleeding score in VKA- or DOAC-treated patients with atrial fibrillation: A systematic review and meta-analysis","volume":"8","author":"Gao","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1253\/circj.CJ-16-0471","article-title":"Is the orbit bleeding risk score superior to the has-bled score in anticoagulated atrial fibrillation patients?","volume":"80","author":"Sogorb","year":"2016","journal-title":"Circ. J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1378\/chest.12-0608","article-title":"Predictive value of the has-bled and atria bleeding scores for the risk of serious bleeding in a \u201creal-world\u201d population with atrial fibrillation receiving anticoagulant therapy","volume":"143","author":"Gallego","year":"2013","journal-title":"Chest"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/ehjqcco\/qcab028","article-title":"Garfield-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation","volume":"8","author":"Fox","year":"2021","journal-title":"Eur. Heart J.\u2014Qual. Care Clin. Outcomes"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Proietti, M., Rivera-Caravaca, J.M., Esteve-Pastor, M.A., Romiti, G.F., Marin, F., and Lip, G.Y. (2018). Predicting bleeding events in anticoagulated patients with atrial fibrillation: A comparison between the has-bled and Garfield-AF Bleeding Scores. J. Am. Heart Assoc., 7.","DOI":"10.1161\/JAHA.118.009766"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1161\/CIRCULATIONAHA.123.064556","article-title":"Development and validation of the DOAC score: A novel bleeding risk prediction tool for patients with atrial fibrillation on direct-acting oral anticoagulants","volume":"148","author":"Aggarwal","year":"2023","journal-title":"Circulation"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e000279","DOI":"10.1136\/openhrt-2015-000279","article-title":"NOACs versus warfarin for stroke prevention in patients with AF: A systematic review and meta-analysis","volume":"3","author":"Hicks","year":"2016","journal-title":"Open Heart"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ahj.2009.07.035","article-title":"Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: Design and rationale","volume":"159","author":"Lopes","year":"2010","journal-title":"Am. Heart J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1161\/circ.124.suppl_21.A16903","article-title":"Predictors of major bleeding risk: Insights from the Rivaroxaban Once-daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)","volume":"124","author":"Goodman","year":"2011","journal-title":"Circulation"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","article-title":"Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation\u2014The J-ROCKET AF study","volume":"76","author":"Hori","year":"2012","journal-title":"Circ. J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","article-title":"Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial","volume":"123","author":"Eikelboom","year":"2011","journal-title":"Circulation"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."}],"container-title":["Clinics and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2039-7283\/14\/1\/27\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:58:50Z","timestamp":1760104730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2039-7283\/14\/1\/27"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,12]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["clinpract14010027"],"URL":"https:\/\/doi.org\/10.3390\/clinpract14010027","relation":{},"ISSN":["2039-7283"],"issn-type":[{"type":"electronic","value":"2039-7283"}],"subject":[],"published":{"date-parts":[[2024,2,12]]}}}